CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Pharmacyclics, Inc.

PCYC
N/A

Next catalyst

Phase 3December 2026

Ibrutinib

Diffuse Large B Cell Lymphoma Relapsed

Get an email about PCYC's next catalysts

Track Pharmacyclics (PCYC) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 2 more upcoming events in our data (Phase 3 readout, Phase 2 readout).See the timeline

Catalyst Timeline

3 upcoming, 0 past

Phase 3Next

Ibrutinib Phase 3 Est. Readout (CAN3001)

December 2026~Ibrutinib539

Estimated primary completion for Ibrutinib trial (NCT01804686) in Chronic Lymphocytic Leukemia. Topline data typically follows completion by weeks to months.

Source
Phase 3

Ibrutinib Phase 3 Est. Readout

March 2027~Ibrutinib23

Estimated primary completion for Ibrutinib trial (NCT04212013) in Marginal Zone Lymphoma. Topline data typically follows completion by weeks to months.

Source
Phase 2

Ibrutinib Phase 2 Est. Readout

April 2027~Ibrutinib40

Estimated primary completion for Ibrutinib trial (NCT04450173) in Ann Arbor Stage II Follicular Lymphoma. Topline data typically follows completion by weeks to months.

Source

Market Overview

Stock performance and key metrics

NASDAQBiotechnology🇺🇸North America
Drug Pipeline

Motexafin Gadolinium

Phase 3

Brain Neoplasms

PCI-32765 (Ibrutinib)

Phase 3

Lymphoma

MGd

Phase 3

Metastatic Cancer

Ibrutinib (as Subsequent Therapy)

Phase 3

Leukemia, Lymphocytic, Chronic, B-Cell

Prednisone (or equivalent)

Phase 3

Lymphoma

Ibrutinib Oral Capsule

Phase 3

Follicular Lymphoma

Next-line ibrutinib

Phase 3

Chronic Lymphocytic Leukemia

Ibrutinib

Phase 3

Diffuse Large B Cell Lymphoma Relapsed

ofatumumab

Phase 3

B-cell Chronic Lymphocytic Leukemia

Chlorambucil

Phase 3

Chronic Lymphocytic Leukemia

Fludarabine

Phase 2

Chronic Lymphocytic Leukemia

HD- Methotrexate (MTX)

Phase 2

Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)

Cirmtuzumab (2-16 kg/mg) plus Ibrutinib

Phase 2

B-cell Chronic Lymphocytic Leukemia

Rituximab + HD- Methotrexate (MTX)

Phase 2

Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)

procarbazine

Phase 2

Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL)

DA-EPOCH-R

Phase 2

Diffuse Large B Cell Lymphoma Relapsed

Pneumococcal 13-valent Conjugate Vaccine

Phase 2

Chronic Lymphocytic Leukemia

Trivalent Influenza Vaccine

Phase 2

Chronic Lymphocytic Leukemia

Cirmtuzumab plus Ibrutinib

Phase 2

B-cell Chronic Lymphocytic Leukemia

Cirmtuzumab (RDR) plus ibrutinib

Phase 2

B-cell Chronic Lymphocytic Leukemia

PCI-24781

Phase 2

Lymphoma

MEDI4736

Phase 2

Diffuse Large B-Cell Lymphoma

Motexafin Gadolinium Injection

Phase 2

Multiple Myeloma

PCI-27483

Phase 2

Pancreatic Cancer

PCI-32765

Phase 2

B-cell Chronic Lymphocytic Leukemia

GA101

Phase 2

Chronic Lymphocytic Leukemia

Blinatumomab

Phase 2

Adult B Acute Lymphoblastic Leukemia

Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed

Phase 2

Chronic Lymphocytic Leukemia

GCSF

Phase 2

Sarcoma

Frequently asked questions

What is in Pharmacyclics, Inc.'s drug pipeline?→

CatalystAlert tracks 29 drug candidates in Pharmacyclics, Inc.'s (PCYC) pipeline across Phase 3, Phase 2. Its lead program is Ibrutinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Pharmacyclics, Inc.'s next FDA catalyst?→

Pharmacyclics, Inc.'s (PCYC) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track PCYC biotech catalysts?→

Add PCYC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Pharmacyclics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply